Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

464 public trials 49 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Active, not recruiting

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

NCT06700343

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • University of South Alabama Mobile, Alabama, United States
  • Clinical Endpoints, LLC Scottsdale, Arizona, United States
  • Profound Research - Neurology Center of Southern California Carlsbad, California, United States
  • Mountain Neurological Research Center Basalt, Colorado, United States
View all 109 locations
View Trial Details
Active, not recruiting

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • University of Colorado-Anschutz Medical Campus Aurora, Colorado, United States
  • University of Minnesota Minneapolis, Minnesota, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada, United States
View all 30 locations
View Trial Details
Active, not recruiting

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

NCT04688788

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +13 more
Locations
  • Danish Multiple Sclerosis Center, Rigshospitalet Glostrup Municipality, Copenhagen, Denmark
  • Department of Neurology, Aalborg University Hospital Aalborg, Denmark
  • Department of Neurology, Aarhus University Hospital Aarhus, Denmark
  • Department of Neurology, Hospital of South West Jutland, Esbjerg Esbjerg, Denmark
View Trial Details
Active, not recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

NCT07667322

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +10 more
Locations
  • Profound Research, LLC Carlsbad, California, United States
  • Neurology Associates, PA Maitland, Florida, United States
  • University of South Florida Tampa, Florida, United States
  • Shepherd Center Inc. Atlanta, Georgia, United States
View Trial Details
Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • North Central Neurology Associates Cullman, Alabama, United States
  • Alabama Neurology Associates Homewood, Alabama, United States
  • 21st Century Neurology Phoenix, Arizona, United States
  • Profound Research, LLC Carlsbad, California, United States
View all 120 locations
View Trial Details
Active, not recruiting

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • UC San Diego La Jolla, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Children's National Hospital Washington D.C., District of Columbia, United States
  • Johns Hopkins Medicine Baltimore, Maryland, United States
View all 71 locations
View Trial Details

Related conditions